InsiderTrades

Form 4 for BBIO BridgeBio Pharma, Inc.

Accepted 2026-06-24 18:06:29 ET · period of report 2026-06-22 · accession 0001470831-26-000636 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DT 2026-06-24 18:06 2026-06-22 BBIO Cook Jennifer E. Dir A - Grant $0.00 +3,990 10.6K +61% $0
DMT 2026-06-24 18:06 2026-06-23+ BBIO Cook Jennifer E. Dir S - Sale+OE $69.92 -39.4K 8,383 -82% -$2.75M
DMT 2026-06-24 18:06 2026-06-24 BBIO Cook Jennifer E. Dir M - OptEx $12.28 +37.2K 45.5K +443% +$456.5K
DT 2026-06-24 18:06 2026-06-22 BBIO Cook Jennifer E. Dir A - Grant $0.00 +5,277 5,277 New $0
DMT 2026-06-24 18:06 2026-06-24 BBIO Cook Jennifer E. Dir M - OptEx $0.00 -37.2K 17.2K -68% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-06-22 A A 3,990 $0.00 10,579 D — — (F1) Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date. (F2) Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
2 Common Common Stock 2026-06-23 S D 2,196 $68.57 8,383 D — — (F3) This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026.
3 Common Common Stock 2026-06-24 M A 20,000 $8.45 28,383 D — — (F3) This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026.
4 Common Common Stock 2026-06-24 M A 17,167 $16.75 45,550 D — — (F3) This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026.
5 Common Common Stock 2026-06-24 S D 37,167 $70.00 8,383 D — — (F3) This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026.
6 Derivative Stock Option (Right to Buy) 2026-06-22 A A 5,277 $0.00 5,277 D $68.92 · — to 2036-06-21 5,277 Common Stock (F4) The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
7 Derivative Stock Option (Right to Buy) 2026-06-24 M D 20,000 $0.00 19,000 D $8.45 · — to 2032-06-22 20,000 Common Stock (F3) This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026. (F5) 1/3rd of the shares underlying the option will vest on June 22, 2023; thereafter, 1/3rd of the remaining underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on the June 22, 2025, subject to the optionee's continued service on the Board of Directors of the Company.
8 Derivative Stock Option (Right to Buy) 2026-06-24 M D 17,167 $0.00 17,167 D $16.75 · — to 2033-06-21 17,167 Common Stock (F3) This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026. (F6) 1/3rd of the shares underlying the option will vest on June 21, 2024; thereafter, 1/3rd of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company.